Improved Outcomes Using Tacrolimus/Sirolimus for Graft-versus-Host Disease Prophylaxis with a Reduced-Intensity Conditioning Regimen for Allogeneic Hematopoietic Cell Transplant as treatment of Myelofibrosis

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 2, 2010, Pages 281-286

  Snyder, David S ^a   Palmer, Joycelynne ^a   Gaal, Karl ^a   Stein, Anthony S ^a   Pullarkat, Vinod ^a   Sahebi, Firoozeh ^a   Vora, Nyana ^a   Nakamura, Ryotaro ^a   Forman, Stephen J ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Allogeneic transplantation; Myelofibrosis; Reduced intensity conditioning; Tacrolimus sirolimus

Indexed keywords

CYCLOSPORIN A; FLUDARABINE; MELPHALAN; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MALE; MYELOFIBROSIS; OVERALL SURVIVAL; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; SURVIVAL RATE; TREATMENT OUTCOME;

ADULT; AGED; COHORT STUDIES; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; GRAFT VS HOST DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; METHOTREXATE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIMARY MYELOFIBROSIS; SEVERITY OF ILLNESS INDEX; SIROLIMUS; SURVIVAL ANALYSIS; TACROLIMUS; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 75449097356     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.09.020     Document Type: Article

References (29)

1. Patriarca F., Bacigalupo A., Sperotto A., et al. Allogeneic hematopoietic stem cell transplantation in myelofibrosis: the 20-year experience of the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Haematologica 93 (2008) 1514-1522
2. Kerbauy D.M.B., Gooley T.A., Sale G.E., et al. Hematopoietic cell transplantation as curative therapy for idiopathic myelofibrosis, advanced polycythemia vera, and essential thrombocythemia. Biol Blood Marrow Transplantat 13 (2007) 355-365
3. Papageorgiou S.G., Castleton A., Bloor A., and Kottaridis P.D. Allogeneic stem cell transplantation as treatment for myelofibrosis. Bone Marrow Transplant 38 (2006) 721-727
4. Rondelli D., Barosi G., Bacigalupo A., et al. Allogeneic hematopoietic stem cell transplantation with reduced intensity conditioning in intermediate or high risk patients with myelofibrosis with myeloid metaplasia. Blood 105 (2005) 4115-4119
5. Snyder D.S., Palmer J., Stein A.S., et al. Allogeneic hematopoietic cell transplantation following reduced intensity conditioning for treatment of myelofibrosis. Biol Blood Marrow Transplant 12 (2006) 1161-1168
6. Merup M., Lazarevic V., Nahi H., et al. Different outcome of allogeneic transplantation in myelofibrosis using conventional or reduced-intensity conditioning regimens. Br J Haematol 135 (2006) 367-373
7. George B., Kerridge I., Gottlieb D., et al. A reduced intensity conditioning protocol associated with excellent survival in patients with myelofibrosis. Bone Marrow Transplant 42 (2008) 567-568
8. Gupta V., Kroger N., Aschan J., et al. A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplant 44 (2009) 317-320
9. Rondelli D. Allogeneic hematopoietic stem cell transplantation for myelofibrosis. Haematologica 93 (2008) 1449-1450
10. Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 10 (2004) 328-336
11. Cutler C., Li S., Ho V.T., et al. Extended follow-up of methotrexate-free immunosuppression using sirolimus and tacrolimus in related and unrelated donor peripheral blood stem cell transplantation. Blood 109 (2007) 3108-3114
12. Alyea E.P., Li S., Kim H.T., et al. Sirolimus, tacrolimus, and low-dose methotrexate as graft-versus-host disease prophylaxis in related and unrelated donor reduced-intensity conditioning allogeneic peripheral blood stem cell transplantation. Biol Blood Marrow Transplant 14 (2008) 920-926
13. Cutler C., Stevenson K., Kim H.T., et al. Sirolimus is associated with veno-occlusive disease of the liver after myeloablative allogeneic stem cell transplantation. Blood 112 (2008) 4425-4431
14. Furlong T., Kiem H.P., Appelbaum F.R., et al. Sirolimus in combination with cyclosporine or tacrolimus plus methotrexate for prevention of graft-versus-host disease following hematopoietic cell transplantation from unrelated donors. Biol Blood Marrow Transplantat 14 (2008) 531-537
15. Platzbecker U., von Bonin M., Goekkurt E., et al. Graft-versus-host disease prophylaxis with everolimus and tacrolimus is associated with a high incidence of sinusoidal obstruction syndrome and microangiopathy: results of the EVTAC trial. Biol Blood Marrow Transplant 15 (2009) 101-108
16. Cervantes F., Dupriez B., Pereira A., et al. A new prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 113 (2009) 2895-2901
17. Thiele J., Kvasnicka H.M., Facchetti F., Franco V., van der Walt J., and Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 90 (2005) 1128-1132
18. Hussein K., Van Dyke D.L., and Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol 82 (2009) 329-338
19. Barosi G., Bordessoule D., Briere J., et al. Response criteria for myelofibrosis with myeloid metaplasia: results of an initiative of the European Myelofibrosis Network (EUMNET). Blood 106 (2005) 2849-2853
20. Jabbour E., and Verstovsek S. Treatment of myelofibrosis in younger patients: to transplant or not?. Am J Hematol 84 (2009) 131-132
21. Wolff D., Andree H., Hilgendorf I., Casper J., Freund M., and Junghanss C. Sirolimus in combination with tacrolimus in allogeneic stem cell transplantation-timing and conditioning regimen may be crucial. Biol Blood Marrow Transplant 14 (2008) 942-943
22. Ciurea S.O., Sadegi B., Wilbur A., et al. Effects of extensive splenomegaly in patients with myelofibrosis undergoing a reduced intensity allogeneic stem cell transplantation. Br J Haematol 141 (2008) 80-83
23. Tefferi A. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy. Am J Hematol 83 (2008) 491-497
24. Ditschkowski M., Elmaagacli A.H., Trenschel R., Steckel N.K., Koldehoff M., and Beelen D.W. No influence of V617F mutation in JAK2 on outcome after allogeneic hematopoietic stem cell transplantation (HSCT) for myelofibrosis. Biol Blood Marrow Transplantat 12 (2006) 1350-1351
25. Fiorini A., Reddiconto G., Farina G., et al. Eradication of JAK2 V617F mutation after allogeneic transplantation in a patient with myelofibrosis with myeloid metaplasia. Leukemia 20 (2006) 2198-2199
26. Kroger N., Badbaran A., Holler E., et al. Monitoring of the JAK2-V617F mutation by highly sensitive quantitative real-time PCR after allogeneic stem cell transplantation in patients with myelofibrosis. Blood 109 (2007) 1316-1321
27. Steckel N.K., Koldehoff M., Ditschkowski M., Beelen D.W., and Elmaagacli A.H. Use of the activating gene mutation of the tyrosine kinase (VAL617Phe) JAK2 as a minimal residual disease marker in patients with myelofibrosis and myeloid metaplasia after allogeneic stem cell transplantation. Transplantation 83 (2007) 1518-1520
28. Kroger N., Alchalby H., Klyuchnikov E., et al. JAK2-V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 113 (2009) 1866-1868
29. Benjamini O., Koren-Michowitz M., Amariglio N., Kroger N., Nagler A., and Shimoni A. Relapse of postpolycythemia myelofibrosis after allogeneic stem cell transplantation in a polycythemic phase: successful treatment with donor lymphocyte infusion directed by quantitative PCR test for V617F-JAK2 mutation. Leukemia 22 (2008) 1961-1963